AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35422240 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy (AAD)
Number of subjects: 144
Study 34599031 — intervention group
Group type: EXPERIMENTAL
Intervention: Seviprotimut-L 40 mcg
Number of subjects: 347
Study 34599031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study 34509591 — intervention group
Group type: EXPERIMENTAL
Intervention: DB+ALSA
Number of subjects: 20
Study 34509591 — intervention group
Group type: COMPARATOR
Intervention: DB‐ACLR
Number of subjects: 20
Study 33148211 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement-to-music video program (8-week exercise intervention)
Number of subjects: 108
Study 33148211 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 108
Study 35039305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy
Number of subjects: 72
Study 35039305 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injections
Number of subjects: 72
Study 35039305 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 33404659 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus belimumab
Number of subjects: 1684
Study 34862877 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirena
Number of subjects: 60
Study 34862877 — intervention group
Group type: COMPARATOR
Intervention: Dydrogesterone
Number of subjects: 60
Study 34342477 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counselling
Number of subjects: 208
Study 34342477 — intervention group
Group type: COMPARATOR
Intervention: Routine surveillance by local health authority (Control)
Number of subjects: 208
Study 32289380 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (D) and Prednisone (P) based regimen
Number of subjects: 8820
Study 35271539 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training using a motion-based digital therapeutic device
Number of subjects: 363
Study 35271539 — intervention group
Group type: COMPARATOR
Intervention: Home pelvic floor muscle training program using written and narrated instructions
Number of subjects: 363
Study 34677136 — intervention group
Group type: EXPERIMENTAL
Intervention: Instagram ads (unlabeled ad condition)
Number of subjects: 832
Study 34677136 — intervention group
Group type: COMPARATOR
Intervention: Traditional ads (unlabeled ad condition)
Number of subjects: 832
Study 34677136 — intervention group
Group type: EXPERIMENTAL
Intervention: Instagram ads (labeled ad condition)
Number of subjects: 832
Study 34677136 — intervention group
Group type: COMPARATOR
Intervention: Traditional ads (labeled ad condition)
Number of subjects: 832
Study 35606882 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-curcumin (80 mg/day)
Number of subjects: 44
Study 35404648 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented vocational rehabilitation (VR) including 12 weeks of social cognition skills training (SCST) plus 6 weeks of work-related social problem solving skills training (SPSST)
Number of subjects: 91
Study 35404648 — intervention group
Group type: COMPARATOR
Intervention: Control VR group with symptom management training matched in instructional format and length to SCST and SPSST
Number of subjects: 91
Study 33106087 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk ladder
Number of subjects: 372
Study 33106087 — intervention group
Group type: COMPARATOR
Intervention: Bulleted list
Number of subjects: 372
Study 33106087 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified table
Number of subjects: 372
Study 33106087 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized vertical bar graph (risk ladder)
Number of subjects: 372
Study 33318632 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse Chromatin Immunoprecipitation (R-ChIP)
Number of subjects: 0
Study 33318632 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcription factors (bZIP1664, TEM1, bHLH106, BTF3, HAT1)
Number of subjects: 0
Study 33318632 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved R-ChIP method using transiently introduced DNA
Number of subjects: 0
Study 34635802 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg/day
Number of subjects: 62
Study 34635802 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg/day
Number of subjects: 62
Study 34635802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 32940890 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 200
Study 32940890 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet adjustments
Number of subjects: 200
Study 32980280 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain medication (paracetamol, NSAID, opioids, neuropathic pain medication)
Number of subjects: 363
Study 32980280 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropathic pain medication
Number of subjects: 363
Study 32980280 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain status (no pain, nociceptive pain, neuropathic pain)
Number of subjects: 363
Study 36003921 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar transforaminal epidural block (LTEB)
Number of subjects: 100
Study 36003921 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (Control)
Number of subjects: 100
Study 33222502 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS+/rTMS-
Number of subjects: 65
Study 32293286 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse Probability of Treatment Weighting (IPTW)
Number of subjects: 60
Study 32293286 — intervention group
Group type: COMPARATOR
Intervention: Regression adjustment
Number of subjects: 60
Study 34813414 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin 1 ng/kg/min infusion for 72 hours
Number of subjects: 80
Study 34813414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 34813414 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin
Number of subjects: 80
Study 32023547 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (a‐tDCS) at 1.5 mA for 15 min
Number of subjects: 12
Study 32023547 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 12
Study 35138376 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI combined with PWI (PVI+PWI)
Number of subjects: 100
Study 35138376 — intervention group
Group type: COMPARATOR
Intervention: PVI only
Number of subjects: 100
Study 34397543 — intervention group
Group type: EXPERIMENTAL
Intervention: De-epithelialization
Number of subjects: 64
Study 34397543 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 64
Study 32644264 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced carbohydrate counting (ACC)
Number of subjects: 87
Study 32644264 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrition education (Control)
Number of subjects: 87
Study 34402352 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracerebral stereotactic implantation of modified bone marrow-derived mesenchymal stromal (SB623) cells
Number of subjects: 61
Study 35710481 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI/cetuximab
Number of subjects: 236
Study 35710481 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI/bevacizumab
Number of subjects: 236
Study 34238020 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 0
Study 34238020 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (control)
Number of subjects: 0
Study 33049035 — intervention group
Group type: EXPERIMENTAL
Intervention: DTG + 3TC
Number of subjects: 0
Study 36078842 — intervention group
Group type: COMPARATOR
Intervention: Traditional material
Number of subjects: 0
Study 34074973 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound-guided dry-weight reduction
Number of subjects: 71
Study 32035624 — intervention group
Group type: EXPERIMENTAL
Intervention: Preflushing with saline at high speed (10 ml/s) before connecting to the catheter
Number of subjects: 4900
Study 32035624 — intervention group
Group type: COMPARATOR
Intervention: Conventional injection procedure (control group)
Number of subjects: 4900
Study 32035624 — intervention group
Group type: EXPERIMENTAL
Intervention: Preflushing with saline
Number of subjects: 4900
Study 35655739 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message-based rehabilitation program (TextRehab)
Number of subjects: 40
Study 35655739 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 34816795 — intervention group
Group type: COMPARATOR
Intervention: Immediate oral amoxicillin (dose-by-age) given three times daily for 7 days
Number of subjects: 22
Study 34816795 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed oral amoxicillin (dose-by-age) given three times daily for 7 days
Number of subjects: 22
Study 34816795 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate topical ciprofloxacin (0.3%) solution, four drops given three times daily for 7 days
Number of subjects: 22
Study 33349617 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-item Social Media Disorder scale
Number of subjects: 1729
Study 35436622 — intervention group
Group type: EXPERIMENTAL
Intervention: Teens Achieving Mastery over Stress (TEAMS)
Number of subjects: 0
Study 35436622 — intervention group
Group type: EXPERIMENTAL
Intervention: Competent Adulthood Transition with Cognitive Behavioral, Humanistic and Interpersonal Training (CATCH-IT)
Number of subjects: 0
Study 34192431 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab group (subcutaneous daratumumab followed by single-agent daratumumab every 4 weeks for up to 24 cycles)
Number of subjects: 388
Study 34192431 — intervention group
Group type: COMPARATOR
Intervention: Control group (bortezomib, cyclophosphamide, and dexamethasone alone)
Number of subjects: 388
Study 34192431 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab group
Number of subjects: 388
Study 34192431 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 388
Study 32970482 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable activity tracker (band) worn for 60 days
Number of subjects: 41
Study 32970482 — intervention group
Group type: COMPARATOR
Intervention: ECOG score assessments by physicians, coordinators, and patients
Number of subjects: 41
Study 34491046 — intervention group
Group type: EXPERIMENTAL
Intervention: Air cleaner intervention
Number of subjects: 125
Study 36143902 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment with nitinol stents (NS)
Number of subjects: 103
Study 36143902 — intervention group
Group type: COMPARATOR
Intervention: Vein bypass surgery
Number of subjects: 103
Study 33225990 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning therapy throughout the day as long as possible, with breaks according to tolerance.
Number of subjects: 200
Study 33225990 — intervention group
Group type: COMPARATOR
Intervention: Control group allowed prone positioning as a rescue therapy.
Number of subjects: 200
Study 35792053 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach bias modification (ApBM)
Number of subjects: 300
Study 35792053 — intervention group
Group type: COMPARATOR
Intervention: Control (sham training)
Number of subjects: 300
Study 34001215 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP), 2 units at screening/baseline visit (day 0) or day 1; additional unit on day 3 for individuals ≥150 kg
Number of subjects: 994
Study 34001215 — intervention group
Group type: EXPERIMENTAL
Intervention: Camostat mesylate (200 mg per capsule, one capsule taken each in the morning, afternoon, and evening on days 1-7)
Number of subjects: 994
Study 34001215 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC)
Number of subjects: 994
Study 34001215 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical in appearance to camostat mesylate capsules, one capsule taken each morning, afternoon, and evening on days 1-7)
Number of subjects: 994
Study 32282842 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga program (90 min once a week for 10 weeks)
Number of subjects: 14
Study 32282842 — intervention group
Group type: COMPARATOR
Intervention: Conventional school sports (90 min once a week for 10 weeks)
Number of subjects: 14
Study 34740607 — intervention group
Group type: EXPERIMENTAL
Intervention: Baked milk oral immunotherapy (BMOIT)
Number of subjects: 30
Study 34740607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 34054034 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient modifications and individual foods/drinks investigated in experimental studies (9 nutrient modifications, 34 individual foods/drinks)
Number of subjects: 31
Study 34054034 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient modifications, foods/drinks, and eating-related behaviors investigated in pre-post studies (10 nutrient modifications, 80 foods/drinks, 11 eating-related behaviors)
Number of subjects: 31
Study 34054034 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient modifications, foods/drinks, and eating-related behaviors reported in observational studies (8 nutrient modifications, 94 foods/drinks, 5 eating-related behaviors)
Number of subjects: 31
Study 34054034 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations from expert opinion articles/guidelines (51 nutrient modifications, 339 foods/drinks, 23 eating-related behaviors)
Number of subjects: 31
Study 34642494 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepirovirsen 300 mg
Number of subjects: 31
Study 34642494 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepirovirsen 150 mg
Number of subjects: 31
Study 34642494 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable NA therapy with Bepirovirsen
Number of subjects: 31
Study 34642494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 34642494 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepirovirsen
Number of subjects: 31
Study 36065065 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir
Number of subjects: 1187
Study 36065065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1187
Study 33426777 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard methods group (n = 177)
Number of subjects: 353
Study 33426777 — intervention group
Group type: COMPARATOR
Intervention: Vignette group (n = 176)
Number of subjects: 353
Study 33506632 — intervention group
Group type: EXPERIMENTAL
Intervention: RME (Rapid Maxillary Expansion)
Number of subjects: 59
Study 33506632 — intervention group
Group type: EXPERIMENTAL
Intervention: Alt-RAMEC (Alternate Rapid Maxillary Expansion and Constriction)
Number of subjects: 59
Study 33506632 — intervention group
Group type: EXPERIMENTAL
Intervention: SA (Skeletal Anchorage)
Number of subjects: 59
Study 35182513 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily risdiplam
Number of subjects: 0
Study 35182513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32868247 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified CAC scan (80 kVp, reduced z-axis length focused on proximal-to-mid coronary arteries)
Number of subjects: 172
Study 32868247 — intervention group
Group type: COMPARATOR
Intervention: Standard Agatston CAC scan (120 kVp)
Number of subjects: 172
Study 32868247 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (modified and standard CAC scans)
Number of subjects: 172
Study 33757745 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine
Number of subjects: 300
Study 33757745 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine
Number of subjects: 300
Study 32127848 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg intravenously
Number of subjects: 108
Study 32127848 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 1.0 µg/kg intravenously
Number of subjects: 108
Study 35648305 — intervention group
Group type: EXPERIMENTAL
Intervention: Qizi Yusi Pill (QYP)
Number of subjects: 124
Study 35648305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 34034808 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulforaphane (SF)
Number of subjects: 57
Study 34034808 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 57
Study 32207010 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid fuels (wood, LPG, charcoal)
Number of subjects: 1734
Study 32207010 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cooking fuels
Number of subjects: 1734
Study 32207010 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic factors, family size, woman's education, age
Number of subjects: 1734
Study 33001422 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI (Angiotensin Converting Enzyme Inhibitor)
Number of subjects: 273
Study 33001422 — intervention group
Group type: COMPARATOR
Intervention: ARB (Angiotensin II Type I Receptor Blocker)
Number of subjects: 273
Study 33001422 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI
Number of subjects: 273
Study 33001422 — intervention group
Group type: COMPARATOR
Intervention: ARB
Number of subjects: 273
Study 32660143 — intervention group
Group type: EXPERIMENTAL
Intervention: Iprodione treatment on mutant M0
Number of subjects: 112
Study 32660143 — intervention group
Group type: EXPERIMENTAL
Intervention: Iprodione treatment on mutant M1
Number of subjects: 112
Study 32660143 — intervention group
Group type: COMPARATOR
Intervention: Iprodione treatment on wild type W0
Number of subjects: 112
Study 32660143 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA sequencing of mutant M‐ipro
Number of subjects: 112
Study 32660143 — intervention group
Group type: COMPARATOR
Intervention: RNA sequencing of wild type W‐ipro
Number of subjects: 112
Study 32660143 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative real-time PCR validation of DEGs
Number of subjects: 112
Study 32660143 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene ontology and KEGG pathway analysis
Number of subjects: 112
Study 34305036 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidulated phosphate fluoride gel (APF)
Number of subjects: 44
Study 34305036 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral fluoride gel (NGel)
Number of subjects: 44
Study 34305036 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (FVa)
Number of subjects: 44
Study 34305036 — intervention group
Group type: COMPARATOR
Intervention: Without fluoride treatment (control)
Number of subjects: 44
Study 32559392 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) sessions (four 45- to 60-minute sessions)
Number of subjects: 140
Study 32559392 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MI sessions)
Number of subjects: 140
Study 32559392 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 140
Study 35543130 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioembolism
Number of subjects: 264
Study 35543130 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolic stroke of undetermined source (ESUS)
Number of subjects: 264
Study 35543130 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissection
Number of subjects: 264
Study 33646044 — intervention group
Group type: EXPERIMENTAL
Intervention: Q203
Number of subjects: 344
Study 32492104 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise ECG
Number of subjects: 3283
Study 32492104 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CT angiography
Number of subjects: 3283
Study 32492104 — intervention group
Group type: COMPARATOR
Intervention: Exercise ECG alone
Number of subjects: 3283
Study 36078489 — intervention group
Group type: EXPERIMENTAL
Intervention: Running-specific strength training group (RSSTG)
Number of subjects: 30
Study 36078489 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training group (ETG)
Number of subjects: 30
Study 36078489 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent training group (CTG)
Number of subjects: 30
Study 34587808 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g intravenous (IV) tranexamic acid (TXA) at the time of surgery and an additional 24-hour postoperative oral regime of four 1 g doses
Number of subjects: 552
Study 34587808 — intervention group
Group type: COMPARATOR
Intervention: Single preoperative intravenous dose of 1 g TXA
Number of subjects: 552
Study 34587808 — intervention group
Group type: COMPARATOR
Intervention: No TXA administered
Number of subjects: 552
Study 32387140 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive Writing (EW) intervention
Number of subjects: 138
Study 36058362 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature walk
Number of subjects: 37
Study 36058362 — intervention group
Group type: COMPARATOR
Intervention: Urban walk
Number of subjects: 37
Study 34550055 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis, BB-12® (1×10^9 cfu/day)
Number of subjects: 192
Study 34550055 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis, BB-12®
Number of subjects: 192
Study 34800364 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 plus the influenza vaccine
Number of subjects: 431
Study 34800364 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus the influenza vaccine
Number of subjects: 431
Study 34800364 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373
Number of subjects: 431
Study 34800364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study 33514449 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (bempedoic acid 180 mg, ezetimibe 10 mg, atorvastatin 20 mg)
Number of subjects: 63
Study 33514449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 32335844 — intervention group
Group type: EXPERIMENTAL
Intervention: BIIB059 (anti-BDCA2 monoclonal antibody) administered intravenously and subcutaneously, dosage not specified.
Number of subjects: 109
Study 35271465 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 96
Study 35271465 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular surgery
Number of subjects: 96
Study 35271465 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 96
Study 34406350 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact force‐guided radiofrequency ablation
Number of subjects: 346
Study 34406350 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐minute cryoballoon ablation
Number of subjects: 346